SCHEMBL4899688

SCHEMBL4899688

COCCc1ccc(OCC(O)CNC2CCN(C(=O)COc3ccc(C4=NNC(=O)CC4)cc3Cl)C2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATF4 P18848 3/20 0.38
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
HRH1 P35367 2/20 0.37
CCR3 P51677 2/20 0.37
LMNA P02545 1/20 0.37
KDM1A O60341 1/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
PMP22 Q01453 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
ADRB1 P08588 4/20 0.36
NR3C1 P04150 1/20 0.36
ADRB2 P07550 1/20 0.36
CYP2D6 P10635 1/20 0.36
ADRA1A P35348 1/20 0.36
CYP2J2 P51589 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899681 1.00 ATF4 (0.38) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4892502 0.96 ATF4 (0.41) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4903082 0.96 ATF4 (0.41) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4903319 0.95 MAPT (0.39) ATF4MAPTKMT2ALMNANPY1R
SCHEMBL4902189 0.95 MAPT (0.39) ATF4MAPTKMT2ALMNANPY1R
SCHEMBL4903640 0.88 ADRB3 (0.45) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4892581 0.88 ADRB3 (0.45) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4899650 0.86 ATF4 (0.43) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4919914 0.86 ATF4 (0.43) ATF4MAPTKMT2AHRH1CCR3
SCHEMBL4892638 0.86 ATF4 (0.44) ATF4MAPTKMT2AHRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ARTESIAN THERAPEUTICS, INC. (US) 2008-10-16 US claimed
EP-1833480-A2 CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE Artesian Therapeutics, Inc. (US) 2007-09-19 EP claimed
WO-2006060122-A9 CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE ARTESIAN THERAPEUTICS INC (US) 2006-08-17 WO claimed
WO-2006060122-A2 CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE ARTESIAN THERAPEUTICS, INC. (US) 2006-06-08 WO claimed
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ARTESIAN THERAPEUTICS, INC. (US) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255134-A1 Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase ADRB3, PDE3A, ADRB1 ATF4 1399/4885MAPT 2409/4885KMT2A 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.